These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 33596496)
1. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders. O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB Drug Alcohol Depend; 2021 Apr; 221():108555. PubMed ID: 33596496 [TBL] [Abstract][Full Text] [Related]
2. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders. O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735 [TBL] [Abstract][Full Text] [Related]
3. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615 [TBL] [Abstract][Full Text] [Related]
4. Opioid Use Disorder and Prescribed Opioid Regimens: Evidence from Commercial and Medicaid Claims, 2005-2015. Ali MM; Cutler E; Mutter R; Henke RM; O'Brien PL; Pines JM; Mazer-Amirshahi M; Diou-Cass J J Med Toxicol; 2019 Jul; 15(3):156-168. PubMed ID: 31152355 [TBL] [Abstract][Full Text] [Related]
5. State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees. Lindner SR; Hart K; Manibusan B; McCarty D; McConnell KJ JAMA Health Forum; 2023 Jun; 4(6):e231574. PubMed ID: 37351873 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. Samples H; Williams AR; Olfson M; Crystal S J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671 [TBL] [Abstract][Full Text] [Related]
7. Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016. Wei YJ; Chen C; Schmidt SO; LoCiganic WH; Winterstein AG Drug Alcohol Depend; 2019 Nov; 204():107600. PubMed ID: 31586806 [TBL] [Abstract][Full Text] [Related]
8. Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk. Tardelli V; Xu KY; Bisaga A; Levin FR; Fidalgo TM; Grucza RA BMJ Ment Health; 2023 Jul; 26(1):. PubMed ID: 37500184 [TBL] [Abstract][Full Text] [Related]
9. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386 [TBL] [Abstract][Full Text] [Related]
10. Mental health and substance use disorder comorbidities among Medicaid beneficiaries: Associations with opioid use disorder and prescription opioid misuse. Swartz JA; Franceschini D; Scamperle K AIMS Public Health; 2023; 10(3):658-677. PubMed ID: 37842281 [TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of co-occurring substance use in individuals with opioid use disorder. Mahoney JJ; Winstanley EL; Lander LR; Berry JH; Marshalek PJ; Haut MW; Marton JL; Kimble WD; Armistead M; Wen S; Cai Y; Hodder SL Addict Behav; 2021 Mar; 114():106752. PubMed ID: 33348147 [TBL] [Abstract][Full Text] [Related]
13. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362 [TBL] [Abstract][Full Text] [Related]
14. Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder. Ellis MS; Xu KY; Tardelli VS; Fidalgo TM; Buttram ME; Grucza RA JAMA Psychiatry; 2023 Dec; 80(12):1269-1276. PubMed ID: 37672238 [TBL] [Abstract][Full Text] [Related]
15. Opioid medication discontinuation and risk of adverse opioid-related health care events. Mark TL; Parish W J Subst Abuse Treat; 2019 Aug; 103():58-63. PubMed ID: 31079950 [TBL] [Abstract][Full Text] [Related]
16. Contraceptive initiation after delivery among women with and without opioid use disorders: A retrospective cohort study in a statewide Medicaid population, 2005-2016. Charron E; Rennert L; Mayo RM; Eichelberger KY; Dickes L; Truong KD Drug Alcohol Depend; 2021 Mar; 220():108533. PubMed ID: 33513446 [TBL] [Abstract][Full Text] [Related]
17. An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program. Cochran G; Gordon AJ; Lo-Ciganic WH; Gellad WF; Frazier W; Lobo C; Chang CH; Zheng P; Donohue JM Med Care; 2017 Mar; 55(3):291-298. PubMed ID: 27984346 [TBL] [Abstract][Full Text] [Related]
18. Treatment utilization among persons with opioid use disorder in the United States. Wu LT; Zhu H; Swartz MS Drug Alcohol Depend; 2016 Dec; 169():117-127. PubMed ID: 27810654 [TBL] [Abstract][Full Text] [Related]
19. Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study. Macmadu A; Paull K; Youssef R; Batthala S; Wilson KH; Samuels EA; Yedinak JL; Marshall BDL Drug Alcohol Depend; 2021 Feb; 219():108435. PubMed ID: 33310383 [TBL] [Abstract][Full Text] [Related]
20. Opioid Use Disorder among Hospitalized Adults in North Carolina: Analysis from the 2000-2020 NC State Inpatient Database. Alemu BT; Beydoun HA; Olayinka O; Harmer B; Brown AR South Med J; 2024 May; 117(5):226-234. PubMed ID: 38701842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]